He was awarded $2.2 million to develop an alternative treatment to target spinal pain outside of invasive surgery.
Dr. Buckley told The Irish Times he plans to inject cells into the spine to understand “the conditions of the center of the disk that would permit regeneration.”
He aims to use engineering principles to better understand cell-based therapy, which could enable patients to delay undergoing an invasive spinal fusion procedure.
More articles on biologics:
Dr. Tony Mork: Reimbursement, lack of training shackles progress of endoscopic spine surgery
Neurosurgeon Dr. Griff Harsh joins ownership group of MLS franchise
DePuy Synthes recalls devices used in spine fixation system: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.